High-quality human disease models are crucial for generating ‘first-in-class’ patient-relevant targets and facilitating the development of novel oncology targets and early-stage drug discovery prog...
"Selexis expertise will be an added value for our molecule,” said Antonio Francesco Di Naro, PhD, Founder, and CEO of ADIENNE Pharma & Biotech. “This collaboration will be fruitful for our company.”